Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 4

PMID 35924243

Authors

Kun Chen

Shuhang Wang

Dan Qi

Peiwen Ma

Yuan Fang

Ning Jiang

Erxi Wu

Ning Li

Affiliations

Soon will be listed here.

Abstract

Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing. However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed. Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries.

Citing Articles

Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT.

Kenyon M, Liptrott S, Kisch A, Mooyaart J, Piepenbroek B, Hutt D Clin Hematol Int. 2024; 6(4):104-113.

PMID: 39564144 PMC: 11574697. DOI: 10.46989/001c.124593.

Optogenetically engineered Septin-7 enhances immune cell infiltration of tumor spheroids.

Chen J, Hnath B, Sha C, Beidler L, Schell T, Dokholyan N Proc Natl Acad Sci U S A. 2024; 121(44):e2405717121.

PMID: 39441641 PMC: 11536090. DOI: 10.1073/pnas.2405717121.

Immunoproteasome acted as immunotherapy 'coffee companion' in advanced carcinoma therapy.

Shi S, Ou X, Liu C, Wen H, Jiang K Front Immunol. 2024; 15:1464267.

PMID: 39281672 PMC: 11392738. DOI: 10.3389/fimmu.2024.1464267.

TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity.

Dharani S, Cho H, Fernandez J, Juillerat A, Valton J, Duchateau P Mol Ther. 2024; 32(11):3915-3931.

PMID: 39169622 PMC: 11573618. DOI: 10.1016/j.ymthe.2024.08.018.

Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.

Holtermann A, Gislon M, Angele M, Subklewe M, von Bergwelt-Baildon M, Lauber K BioDrugs. 2024; 38(5):611-637.

PMID: 39080180 PMC: 11358237. DOI: 10.1007/s40259-024-00669-y.

References

Hernandez-Lopez R, Yu W, Cabral K, Creasey O, Lopez Pazmino M, Tonai Y . T cell circuits that sense antigen density with an ultrasensitive threshold. Science. 2021; 371(6534):1166-1171. PMC: 8025675. DOI: 10.1126/science.abc1855. View

Chow M, Luster A . Chemokines in cancer. Cancer Immunol Res. 2014; 2(12):1125-31. PMC: 4258879. DOI: 10.1158/2326-6066.CIR-14-0160. View

Adusumilli P, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J . Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014; 6(261):261ra151. PMC: 4373413. DOI: 10.1126/scitranslmed.3010162. View

Moon E, Carpenito C, Sun J, Wang L, Kapoor V, Predina J . Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011; 17(14):4719-30. PMC: 3612507. DOI: 10.1158/1078-0432.CCR-11-0351. View

Klichinsky M, Ruella M, Shestova O, Lu X, Best A, Zeeman M . Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020; 38(8):947-953. PMC: 7883632. DOI: 10.1038/s41587-020-0462-y. View

Louis C, Savoldo B, Dotti G, Pule M, Yvon E, Myers G . Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011; 118(23):6050-6. PMC: 3234664. DOI: 10.1182/blood-2011-05-354449. View

Kloss C, Lee J, Zhang A, Chen F, Melenhorst J, Lacey S . Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018; 26(7):1855-1866. PMC: 6037129. DOI: 10.1016/j.ymthe.2018.05.003. View

Qi D, Wu E . Cancer prognosis: Considering tumor and its microenvironment as a whole. EBioMedicine. 2019; 43:28-29. PMC: 6558022. DOI: 10.1016/j.ebiom.2019.04.031. View

Nagarsheth N, Wicha M, Zou W . Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017; 17(9):559-572. PMC: 5731833. DOI: 10.1038/nri.2017.49. View

10.

Payne A, Cornelius L . The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 2002; 118(6):915-22. DOI: 10.1046/j.1523-1747.2002.01725.x. View

11.

Rosenberg S, Packard B, Aebersold P, Solomon D, Topalian S, TOY S . Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319(25):1676-80. DOI: 10.1056/NEJM198812223192527. View

12.

Zhang E, Gu J, Xu H . Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018; 17(1):7. PMC: 5767005. DOI: 10.1186/s12943-018-0759-3. View

13.

Idorn M, Skadborg S, Kellermann L, Halldorsdottir H, Holmen Olofsson G, Met O . Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. Oncoimmunology. 2018; 7(8):e1450715. PMC: 6136860. DOI: 10.1080/2162402X.2018.1450715. View

14.

Gong N, Sheppard N, Billingsley M, June C, Mitchell M . Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021; 16(1):25-36. DOI: 10.1038/s41565-020-00822-y. View

15.

Park J, Geyer M, Brentjens R . CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016; 127(26):3312-20. PMC: 4929923. DOI: 10.1182/blood-2016-02-629063. View

16.

McGrail D, Federico L, Li Y, Dai H, Lu Y, Mills G . Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun. 2018; 9(1):1317. PMC: 5882811. DOI: 10.1038/s41467-018-03730-x. View

17.

Pan G, Ni J, Wei Y, Yu G, Gentz R, Dixit V . An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997; 277(5327):815-8. DOI: 10.1126/science.277.5327.815. View

18.

Knorr D, Ni Z, Hermanson D, Hexum M, Bendzick L, Cooper L . Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013; 2(4):274-83. PMC: 3659832. DOI: 10.5966/sctm.2012-0084. View

19.

Rodriguez P, Zea A, DeSalvo J, Culotta K, Zabaleta J, Quiceno D . L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003; 171(3):1232-9. DOI: 10.4049/jimmunol.171.3.1232. View

20.

Donovan L, Delaidelli A, Joseph S, Bielamowicz K, Fousek K, Holgado B . Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020; 26(5):720-731. PMC: 8815773. DOI: 10.1038/s41591-020-0827-2. View